GlassScriptPhysician profile
Sohaib Lateef
NPI 1790289874
$1,227.89
in general payments reported to CMS, 2019-2025
26 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.42 · 2021: $266 · 2022: $438 · 2023: $343 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $354.01 | 2023-2025 | Linq II |
| Abbvie INC. | $128.36 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $84.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $79.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $75.54 | 2022 | |
| Kyowa Kirin, INC. | $62.57 | 2021-2023 | Nourianz |
| Ucb, INC. | $48.61 | 2021-2023 | Briviact |
| Eisai INC. | $47.79 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.95 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.57 | 2022 | |
| Pfizer INC. | $30.81 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $24.95 | 2021 | |
| Argenx US, INC. | $22.18 | 2022 | |
| Csl Behring | $22.00 | 2021 | |
| Neurelis, INC. | $19.90 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $17.78 | 2022 | |
| Sk Life Science, INC. | $17.64 | 2023 | |
| Merz North America, INC. | $16.36 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.32 | 2023 | Keveyis |
| Acadia Pharmaceuticals INC | $14.32 | 2023 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $14.14 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.00 | 2022 | |
| Biogen, INC. | $13.55 | 2021 | |
| Ptc Therapeutics, INC. | $13.31 | 2022 | |
| Amgen INC. | $11.53 | 2022 | |
| Allergan, INC. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohaib Lateef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.